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Background: Ovarian malignancies are often diagnosed in advanced stage and at the same time resistance to
treatment, both intrinsic and developed during treatment, is sometimes observed. These facts underscore the need
for new markers of ovarian cancer risk, as well as markers of treatment effectiveness.
Methods: In this study we genotyped 225 ovarian cancer patients, 64 breast and ovarian cancer patients and 348
healthy controls. In total, 12 polymorphic variants and 2 deletions in PGR, ABCB1, ABCG2, GSTT1, GSTM1, GSTP1, ATM,
TP53 and ATP7B genes were analyzed using ASA-PCR, RFLP-PCR, multiplex-PCR and sequencing.
Results: Ten genetic polymorphisms were significantly associated with the risk of developing ovarian carcinoma in
at least one of the groups under study. Impact of PGR gene polymorphisms on ovarian cancer risk was specific only
for the group of the BRCA1 mutation carriers (in presence of p.Val660Leu variant- OR 2,82; p = 0,010), which confirms
the difference in modulation of ovarian cancer risk between sporadic and hereditary malignancies, including the
breast-ovarian cancer group (as a cancer-prone group). The analyses showed also the importance of ATP7B gene in
ovarian carcinogenesis, both studied variants of which significantly modulated the ovarian cancer risk in all groups
excluding the group with BRCA1 mutation. Cumulative risk analysis revealed 3 unfavorable variants that increased
significantly the risk of developing ovarian cancer (p.Ile1145 = ABCB1+ p.Asp1853Asn ATM+ p.Ser406Ala ATP7B- OR
7,47; p = 0,002) and significantly modified the progression free survival (PFS) of the patients, and also two favorable
genotypes which protected against ovarian cancer (p.Arg952Lys ATP7B+ p.Arg72Pro TP53- OR 0,50; p = 0,008). PFS
analysis for carriers of favorable versus unfavorable genotypes emphasized the impact of the regulation of cell cycle
(p.Asp1853Asn ATM) and active transport of xenobiotics (p.Ser894Ala/Thr ABCB1) on the risk of disease progression
(HR 3,81; p = 0,010) after paclitaxel/cisplatin chemotherapy.
Conclusions: The unfavorable genetic variants could facilitate carcinogenic process and once their carriers
developed malignancy, their chances of survival were smaller. Our analyses also showed a strong gene-dosage
effect with the decrease of progression-free survival for the carriers of two unfavorable genetic factors.
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Ovarian carcinoma is the sixth leading malignancy diag-
nosed in women and fourth leading cause of cancer mor-
tality in Silesia, a southern province of Poland [1]. Poland
belongs to the countries with high morbidity rates for
ovarian carcinoma - epidemiologic data show steady rise* Correspondence: ewagrzybowska@yahoo.com
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for different continents and geographic regions, countries,
races and ethnic groups. Malignancies of the ovary are
diagnosed frequently in advanced stage in postmeno-
pausal women, contributing to a relatively high mortal-
ity and little progress in improving survival rates within
the past few decades [3,4]. These facts emphasize the
necessity of developing better methods of treatment,
diagnosis and prevention. Unfavorable statistics in ovar-
ian cancer patients reflects in part poor understandinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ease [5].
The strongest risk factor of developing ovarian cancer
is the family history of breast and ovarian cancer. About
15% of ovarian cancer patients in Polish population carry
germline mutation in BRCA1/2 genes [6]. A small num-
ber of patients with inherited predisposition to ovarian
carcinoma is also connected with Lynch syndrome and
germline mutations in mismatch repair genes, such as
hMLH1, hMSH2, hMSH6, PMS1 and PMS2 [7,8]. How-
ever, the common genetic polymorphisms can also influ-
ence the risk of developing ovarian carcinoma.
In this study we wanted to evaluate the effects of poly-
morphic variants of the genes connected with progester-
one activity, cell cycle control, and transport systems on
ovarian cancer risk. Besides frequent occurrence of germ-
line mutations in BRCA1/2 genes, ovarian carcinoma is
sometimes accompanied by breast carcinoma, so we di-
vided the group of ovarian cancer patients under study
into four groups: all patients, patients without BRCA1 mu-
tation, patients with germline mutation in BRCA1 gene
and patients who developed both breast and ovarian car-
cinoma. The aim was to find out whether there were dif-
ferences in cancer risk among these groups.
Methods
Patients and controls
A total of 225 case subjects diagnosed with ovarian can-
cer and 64 with breast and ovarian cancer participated
in the analysis. Cases of ovarian malignancies other than
epithelial, i.e. germ cell and sex cord stromal tumors,
were not included in this study. Patients filled an in-
formed consent form and agreed to have their genetic
material used for research purpose. The majority of
patients (186 patients, 82.6%) were diagnosed between
year 2000 and 2006, while 33 women (14.7%) had been
diagnosed during the 1983–1999 time period. Exact diag-
nosis date was not known for 6 (2.7%) patients. Anonym-
ous healthy women (n = 348) forming the control group
were recruited from among female employees of the
Cancer Center and Institute of Oncology in Gliwice and
were matched to the study groups for mean age of ovarian
cancer diagnosis. The study was approved by the appro-
priate bioethics committee. Status of the most common
BRCA1 mutations in Silesian population was determined
for all subjects under study, including the control group.
None of control subjects carried germline mutation in
BRCA1 gene. For statistical analysis, study groups were
divided with respect to the absence of germline mutation
(BRCA1-) or its presence (BRCA1+), or were analyzed as a
total group. For some analyses the calculations were done
for BRCA1- group only as BRCA1+ group was much
smaller and some calculations were not possible. The
group of breast and ovarian cancer cases was analyzedseparately, without BRCA1 mutation-based division due
to small number of subjects. All women in the studied
groups were Caucasian with Silesian descent. The obser-
vation ended on 1st of February 2011. Full clinical charac-
teristics of the patient groups are presented in Table 1.
For survival analysis, 129 ovarian cancer patients diag-
nosed between 2000 and 2006 were selected. These women
underwent primary cytoreduction prior to paclitaxel/
cisplatin first-line chemotherapy. The surgeries were
performed in other hospitals, therefore the data regard-
ing residual disease were not available. Majority of the
selected patients (119 women; 92.2%) were given six
courses of first-line treatment, one patient underwent
eight cycles while nine patients obtained less than six
cycles, due to severe adverse reaction or progression
during treatment, or because of complete response.
Treatment response according to RECIST (version 1.0)
was determined after the completion of chemotherapy.
Complete response (CR) was achieved in 97 patients
(75.2%), whereas 15 subjects (11.6%) showed partial re-
sponse (PR), and four patients (3.1%) progressed (PD)
during treatment. Disease stabilization (SD) was not
observed in selected group of patients. The treatment
response estimation was not available for 13 women
(10.1%).
Clinical endpoints
Overall survival (OS) was calculated as time period (in
months) from diagnosis (established as the surgery date)
to death from any cause, or to date of last contact with
the patient. Median overall survival was 86.8 months;
during the observation 58 patients (45.0%) from the pac-
litaxel/cisplatin group died. Progression-free survival
(PFS) was calculated as time period (in months) from
date of first course of chemotherapy to date of progres-
sion (confirmed by the MRI, CT or ultrasound), or to
date of last contact with the patient. Disease progression
was defined as presence of distant metastasis, the local
recurrences were not analyzed. Progression was con-
firmed in 38 patients (29.5%), while 88 (68.2%) women
had no metastases till the end of observation. Three
patients (2.3%) were rejected from PFS analysis due to
lack of data.
Genes and polymorphism selection
Genes selected for this study represent three functional
groups important in ovarian cancer development and
patients’ prognosis, i.e. hormonal control (PGR- progester-
one receptor), xenobiotics removal (ABCB1- ATP-binding
cassette subfamily B, member 1; ABCG2- ATP-binding
cassette sub-family G, member 2; ATP7B- ATPase, Cu++
transporting, beta polypeptide; GSTT1- glutathione
S-transferase theta 1; GSTM1- glutathione S-transferase
mu 1; GSTP1- glutathione S-transferase pi 1) and DNA
Table 1 Clinical characteristics of patient groups
Ovarian cancer
group (n = 225)
Breast and ovarian
cancer group (n = 64)
Mean age at ovarian cancer
diagnosis in years (range)
48.8 (16.9-70.6) 51.2 (33.8-66.9)
Mean age at breast cancer
diagnosis in years (range)
48.1 (25.0-72.9)
BRCA1 mutation status
• Negative 198 (88.0%) 46 (71.9%)
• Positive 27 (12.0%) 18 (28.1%)
BRCA1 mutation type
• 5382insC (c.5266dupC) 17 (63.0%) 14 (77.8%)
• 300 T/G (c.181 T > G) 8 (29.6%) 2 (11.1%)
• 185delAG (c.68-69delAG) 2 (7.4%) 2 (11.1%)
• 4153delA (c. 4034delA) – –
• 3819del5 (c.3700_3704del5) – –
Ovarian Cancer
FIGO
• I 73 (32.4%) 16 (25.0%)
• II 33 (14.7%) 5 (7.8%)
• III 95 (42.2%) 31 (48.5%)
• IV 13 (5.8%) 2 (3.1%)
• Unspecified/unknown 11 (4.9%) 10 (15.6%)
GRADE
• G1- well differentiated 34 (15.1%) 3 (4.7%)
• G2- moderately
differentiated
98 (43.6%) 20 (31.2%)
• G3- undifferentiated 86 (38.2%) 29 (45.3%)
• G4 1 (0.4%) –
• unspecified/unknown 6 (2.7) 12 (18.8%)
Histology
• Serous 121 (53.8%) 41 (64.1%)
• Mucinous 23 (10.2%) 2 (3.1%)
• Endometrioid 33 (14.7%) 2 (3.1%)
• Clear cell 6 (2.7%) 1 (1.6%)
• Other/unspecified 41 (18.2%) 15 (23.4%)
• Unknown 1 (0.4%) 3 (4.7%)
Breast Cancer
GRADE




• G3- undifferentiated 6 (9.4%)
• Unspecified/unknown 26 (40.6%)
Histology
• Ductal carcinoma in situ 1 (1.6%)
• Ductal carcinoma 44 (68.7%)
• Lobular carcinoma 1 (1.6%)
Table 1 Clinical characteristics of patient groups
(Continued)
• Medullary carcinoma 3 (4.7%)
• Other 13 (20.3%)
• Unspecified 2 (3.1%)
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TP53- tumor protein p53). The selection of polymor-
phisms was based on literature search as well as search
in the public databases (NCBI dbSNP, PharmGKB and
HapMap). All selected variants had MAF higher than
5% in the European Caucasian population.
Genotyping
Genomic DNA was isolated from the peripheral blood
leukocytes using the phenol-chloroform method. Genotyp-
ing was performed using the allele-specific amplification
PCR (ASA-PCR), multiplex-PCR or RFLP-PCR method.
Genotyping of polymorphic variants in PGR (rs10895068
and p.Val660Leu), ABCB1 (p.Ile1145 = and p.Ser893Ala/
Trp), ABCG2 (p.Gln141Lys), ATM (p.Asp1853Asn), TP53
(p.Arg72Pro), GSTP1 (p.Ile105Val) genes, as well as detec-
tion of GSTT1/M1 gene deletions, were performed as
described previously [9-17]. The genotyping methods for
polymorphisms in ATP7B (p.Ser406Ala and p.Arg952Lys),
ABCG2 (rs13120400) and PGR gene (rs474320) were
developed for this study.
Statistical analysis
The difference between observed and expected genotype
frequencies in control and patient groups were tested for
Hardy-Weinberg Equilibrium (HWE) using the χ2 test.
Statistical significance threshold was set at 0.05; all re-
sults with p-value ≤0.1 were seen as trend indicators. In
all analyses, common homozygotes were used as a refer-
ence genotype with respect to heterozygotes, rare homo-
zygotes and rare allele carriers. In case of trinucleotide
polymorphism rs2032582 in ABCB1 gene, an additional
combination was applied, comparing the carriers of
common G allele with the carriers of rare alleles (i.e. T
and A). In case–control analysis, odds ratios (ORs), 95%
confidence intervals (95% CIs) and p values were set to
test associations between genotype distributions in cases
and their controls, and logistic regression model was ap-
plied. Survival curves were derived by Kaplan-Meyer
method, p values were computed by log-rank test. The
relative risk of death and progression was estimated as
hazard ratios (HRs); 95% confidence intervals (95% CIs)
and p value were determined by Cox proportional haz-
ard regression model. SNPs correlated with survival were
re-evaluated in the multivariate analyses adjusted to
known ovarian cancer prognostic factors (cancer histo-
type and FIGO stage). Age at time of diagnosis, tumor
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associated with patients’ survival and these factors were
not included in multivariate model adjustment. All stat-




The SNPs under study did not show significant departure
from Hardy-Weinberg equilibrium with the exception of
GSTP1 p.Ile105Val polymorphism which significantly de-
parted from Hardy-Weinberg equilibrium (p = 0.032) in
the control group (data not shown). Among twelve poly-
morphic variants and two deletions in nine genes under
study we found ten which were significantly associated
with the increased or decreased risk of developing ovarian
carcinoma in at least one of the groups under study
(Table 2).
The total group
For the whole group of ovarian cancer patients the poly-
morphic variants in PGR, ABCB1, GSTT1, GSTM1 and
GSTP1 genes did not change the risk of developing can-
cer. Polymorphism p.Gln141Lys in the ABCG2 gene, bor-
derline significant (OR 0.64; 95% CI 0.40-1.02; p = 0.059),
decreased the risk of ovarian cancer for heterozygotes.
Polymorphic variant p.Asp1853Asn in the ATM gene
showed tendency towards increased risk of ovarian cancer
for heterozygotes (OR 1.40; 95% CI 0.95-2.06; p = 0.091)
and for the carriers of at least one minor A allele (OR
1.43; 95% CI 0.98-2.09; p = 0.061). Significant decrease of
ovarian cancer risk was observed for heterozygotes of p.
Arg72Pro polymorphic variant in TP53 gene (OR 0.68;
95% CI 0.47-0.97; p = 0.031). Two studied variants of
copper transporter ATP7B showed opposite effects on
the ovarian cancer risk. p.Ser406Ala polymorphism was
strongly connected with the increased risk of ovarian
cancer for heterozygotes (OR 1.80; 95% CI 1.17-2.80;
p = 0.008), for minor homozygotes (OR 2.10; 95% CI
1.28-3.46; p = 0.003) and for the carriers of at least one
minor G allele (OR 1.9; 95% CI 1.26-2.88; p = 0.002). For
polymorphic variant p.Arg952Lys in the same gene there
was a trend of protective effect against ovarian cancer
for heterozygotes and minor homozygotes (OR 0.72;
95% CI 0.49-1.06; p = 0.096 and OR 0.64; 95% CI 0.39-
1.04; p = 0.070, respectively). The significant protective
effect was shown for the carriers of at least one G allele
(OR 0.70; 95% CI 0.49-1.00; p = 0.047). Significant effects
were also observed in the analysis of combined GSTT1
and GSTM1 genes’ deletion. Haplotype GSTT1wt/
GSTM1null had protective effect against ovarian cancer
(OR 0.53; 95% CI 0.29-0.98; p = 0.040) when compared
with wt/wt haplotype. Possible increase of ovarian
cancer risk was also shown for minor homozygotes ofpolymorphism p.Ile105Val in the GSTP1 gene (OR
1.73; 95% CI 0.92-3.26; p = 0.090).
For BRCA1- group we observed a significant increase
in cancer risk for the heterozygotes carrying silent poly-
morphism p.Ile1145 = in the ABCB1 gene (OR 1.64; 95%
CI 1.03-2.60; p = 0.036). A less strong effect was observed
for the carriers of at least one T allele (OR 1.47; 95% CI
0.94-2.28; p = 0.089). Also, the presence of polymorphism
p.Ile105Val in GSTP1 gene had lost any statistical signifi-
cance. The rest of polymorphisms under study showed
similar effects on cancer risk as observed in the total
group.
The BRCA1+ group was the only one where p.Val660-
Leu polymorphism in the PGR gene had any impact on
cancer risk. This variant significantly increased the risk
of developing ovarian cancer for heterozygotes (OR 2.94;
95% CI 1.31-6.58; p = 0.009) and for carriers of at least
one minor T allele (OR 2.82; 95% CI 1.28-6.23; p = 0.010).
For the trinucleotide polymorphism (rs2032582) in the
ABCB1 gene there was a tendency towards higher ovarian
cancer risk for rare TA genotype (OR 5.20; 95%CI 0.87-
31.18; p = 0.069). Significantly increased risk of ovarian
cancer in this group was also shown for minor p.Ile105Val
homozygote in GSTP1 gene (OR 3.27; 95% CI 1.03-10.42,
p = 0.044). It should be noted that the BRCA1+ group
was much smaller than the others and for some rare
polymorphic variants the calculations were not possible
as there were no subjects carrying the variant under
study.
Breast and ovarian cancer group
Significant increase of cancer risk was connected with
the p.Asp1853Asn polymorphism in the ATM gene and
minor homozygotes were at higher cancer risk (OR 4.52;
95% CI 1.16-17.56; p = 0.029). Tendency towards in-
creased cancer risk was also found for minor p.Ser406Ala
homozygotes in the ATP7B gene (OR 2.03; 95% CI 0.94-
4.40; p = 0.069) and for carriers of at least one minor allele
G (OR 1.75; 95% CI 0.91-3.36; p = 0.093). The second
polymorphism of this gene (p.Arg952Lys) was significantly
linked with the protective effect against breast and ovarian
cancer (OR 0.40; 95% CI 0.16-0.97; p = 0.041) for the minor
heterozygotes.
Cumulative effects of favorable and unfavorable genotypes
on ovarian cancer risk
To examine the cumulative effects of genetic variants
under study, regarded as the reflection of gene dosage
effect on ovarian cancer risk, analysis of favorable and
unfavorable genotypes was performed. This analysis was
done for the group of sporadic ovarian cancer patients
(BRCA1-) to avoid the strong influence of mutated BRCA1
gene. The polymorphisms, which in univariate analysis
were modulating ovarian cancer risk, were included in the
Table 2 Case–control analyses of ovarian and breast and ovarian cancer risk
Ovarian cancer all patients Ovarian cancer BRCA1- Ovarian cancer BRCA1+ Breast and ovarian cancer
Gene
polymorphism
Genotype Controls n(%) n(%) OR (±95% CI) p n(%) OR (±95% CI) p n(%) OR (±95% CI) p n(%) OR (±95% CI) p
PGR p.Val660Leu
rs1042838
GG 239 (69.3) 143 (63.9) 1(ref) 131 (66.5) 1(ref) 12 (44.4) 1(ref) 46 (75.4) 1 (ref)
GT 95 (27.5) 74 (33.0) 1.03 (0.90-1.88) 0.160 60 (30.5) 1.15 (0.78-1.70) 0.473 14 (51.9) 2.94 (1.31-6.58) 0.009 14 (23.0) 0.77 (0.40-1.46) 0.416
TT 11 (3.2) 7 (3.1) 1.06 (0.40-2.81) 0.901 6 (3.0) 1.00 (0.36-2.75) 0.993 1 (3.70) 1.81 (0.22-15.20) 0.584 1 (1.6) 0.47 (0.06-3.75) 0.478




GG 117 (33.7) 65 (29.0) 1(ref) 56 (28.4) 1(ref) 9 (33.4) 1(ref) 16 (26.2) 1 (ref)
GT 156 (45.0) 115 (51.4) 1.33 (0.90-1.95) 0.152 104 (52.8) 1.39 (0.93-2.09) 0.108 11 (40.7) 0.92 (0.37-2.28) 0.852 33 (54.1) 1.55 (0.71-2.94) 0.184
TT 60 (17.3) 37 (16.5) 1.11 (0.67-1.85) 0.688 32 (16.3) 1.11 (0.65-1.90) 0.691 5 (18.5) 1.08 (0.35-3.38) 0.890 9 (14.8) 1.10 (0.46-2.63) 0.836
GA 9 (2.6) 2 (0.9) 0.40 (0.08-1.91) 0.250 2 (1.0) 0.46 (0.10-2.24) 0.337 – – – 2 (3.3) 1.63 (0.32-8.31) 0.557
TA 5 (1.4) 5 (2.2) 1.80 (0.50-6.45) 0.367 3 (1.5) 1.25 (0.29-5.49) 0.763 2 (7.4) 5.20 (0.87-31.18) 0.069 1 (1.6) 1.46 (0.16-13.6) 0.736
AA – – – – – – – – – – – – –
GG+GT+GA 282 (81.3) 182 (81.3) 1 (ref) 162 (82.2) 1 (ref) 20 (74.1) 1 (ref) 51 (83.6) 1 (ref)
TT + TA 65 (18.7) 42 (18.7) 1.00 (0.92-1.09) 1.000 35 (17.8) 0.94 (0.60-1.48) 0.780 7 (25.9) 1.52 (0.61-3.76) 0.364 10 (16.4) 0.85 (0.41-1.77) 0.664
ABCB1 p.Ile1145=
rs1045642
CC 83 (24.0) 44 (19.6) 1(ref) 35 (17.8) 1(ref) 9 (33.3) 1(ref) 16 (26.2) 1 (ref)
CT 162 (47.0) 122 (54.5) 1.42 (0.92-2.19) 0.113 112 (56.8) 1.64 (1.03-2.60) 0.036 10 (37.1) 0.57 (0.22-1.46) 0.239 26 (42.6) 0.83 (0.42-1.64) 0.596
TT 100 (29.0) 58 (25.9) 1.09 (0.67-1.78) 0.718 50 (25.4) 1.18 (0.70-2.00) 0.522 8 (29.6) 0.74 (0.27-2.00) 0.549 19 (31.2) 0.98 (0.48-2.04) 0.969




CC 276 (80.2) 191 (86.4) 1 (ref) 167 (85.6) 1 (ref) 24 (92.3) 1 (ref) 56 (87.5) 1 (ref)




GG 254 (75.8) 153 (68.6) 1 (ref) 134 (68.4) 1 (ref) 19 (70.4) 1 (ref) 45 (70.3) 1 (ref)
GA 76 (22.7) 64 (28.7) 1.40 (0.95-2.06) 0.091 57 (29.1) 1.42 (0.95-2.13) 0.083 7 (25.9) 1.23 (0.50-3.05) 0.651 15 (23.4) 1.11 (0.59-2.11) 0.740
AA 5 (1.5) 6 (2.7) 1.99 (0.60-6.66) 0.262 5 (2.5) 1.90 (0.54-6.69) 0.319 1 (3.7) 2.67 (0.39-24.29) 0.380 4 (6.3) 4.52 (1.16-17.56) 0.029
GA + AA 81 (24.2) 70 (31.4) 1.43 (0.98-2.09) 0.061 62 (31.6) 1.45 (0.98-2.15) 0.062 8 (29.6) 1.32 (0.73-2.40) 0.352 19 (29.7) 1.32 (0.56-3.14) 0.528
TP53 p.Arg72Pro
rs1042522
GG 167 (49.0) 130 (57.8) 1 (ref) 115 (58.1) 1 (ref) 15 (55.6) 1 (ref) 29 (48.3) 1 (ref)
GC 150 (44.0) 79 (35.1) 0.68 (0.47-0.97) 0.031 70 (35.3) 0.68 (0.47-0.98) 0.039 9 (33.3) 0.67 (0.28-1.57) 0.355 29 (48.3) 1.11 (0.64-1.95) 0.707
CC 24 (7.0) 16 (7.1) 0.86 (0.44-1.68) 0.652 13 (6.6) 0.79 (0.39-1.61) 0.511 3 (11.1) 1.39 (0.38-5.16) 0.621 2 (3.3) 0.48 (0.11-2.14) 0.336
GC + CC 174 (51.0) 95 (42.2) 0.80 (0.61-1.05) 0.104 83 (41.9) 0.69 (0.49-0.99) 0.042 12 (44.4) 0.77 (0.35-1.69) 0.511 31 (51.67) 1.03 (0.59-1.78) 0.927
ATP7B p.Ser406Ala
rs1801243
TT 103 (30.8) 41 (19.0) 1 (ref) 35 (18.5) 1 (ref) 6 (22.2) 1 (ref) 13 (20.3) 1 (ref)
TG 157 (47.0) 113 (52.3) 1.81 (1.17-2.80) 0.008 100 (52.9) 1.87 (1.18-2.97) 0.007 13 (48.2) 1.42 (0.52-3.88) 0.490 32 (50.0) 1.61 (0.81-3.23) 0.174
GG 74 (22.2) 62 (28.7) 2.10 (1.28-3.46) 0.003 54 (28.6) 2.15 (1.27-3.62) 0.004 8 (29.6) 1.86 (0.61-5.61) 0.270 19 (29.7) 2.03 (0.94-4.40) 0.069













Table 2 Case–control analyses of ovarian and breast and ovarian cancer risk (Continued)
ATP7B p.Arg952Lys
rs732774
AA 103 (30.7) 86 (38.9) 1 (ref) 76 (39.2) 1 (ref) 10 (37.0) 1 (ref) 25 (39.7) 1 (ref)
AG 159 (47.5) 96 (43.4) 0.72 (0.49-1.06) 0.096 82 (42.3) 0.70 (0.47-1.04) 0.078 14 (51.9) 0.91 (0.39-2.11) 0.821 31 (49.2) 0.80 (0.45-1.44) 0.471
GG 73 (21.8) 39 (17.7) 0.64 (0.39-1.04) 0.070 36 (18.5) 0.67 (0.41-1.10) 0.112 3 (11.1) 0.42 (0.11-1.61) 0.203 7 (11.1) 0.40 (0.16-0.97) 0.041
AG + GG 232 (69.3) 135 (61.1) 0.70 (0.49-1.00) 0.047 118 (60.8) 0.69 (0.48-1.00) 0.049 17 (63.0) 0.75 (0.33-1.71) 0.499 38 (60.3) 0.67 (0.39-1.18) 0.165
GST T1/M1 Gene
deletions
wt/wt 118 (34.6) 82 (36.8) 1(ref) 72 (36.7) 1(ref) 10 (37.0) 1(ref) 20 (31.3) 1(ref)
wt/null 49 (14.4) 18 (8.1) 0.53 (0.29-0.98) 0.040 17 (8.7) 0.57 (0.30-1.07) 0.076 1 (3.7) 0.24 (0.03-1.96) 0.180 6 (9.4) 0.72 (0.27-1.92) 0.512
null/wt 138 (40.5) 95 (42.6) 0.99 (0.64-1.54) 0.967 82 (41.8) 0.97 (0.65-0.47) 0.90 13 (48.2) 1.11 (0.47-2.64) 0.810 31 (48.4) 1.32 (0.72-2.45) 0.368
null/null 36 (10.5) 28 (12.5) 1.12 (0.63-1.98) 0.698 25 (12.8) 1.14 (0.63-2.06) 0.667 3 (11.1) 0.98 (0.24-4.04) 0.982 7 (10.9) 1.14 (0.45-2.95) 0.774
GSTP1 p.Ile105Val
rs1695
AA 151 (45.2) 104 (46.4) 1 (ref) 93 (47.2) 1 (ref) 11 (40.7) 1 (ref) 32 (52.4) 1 (ref)
AG 162 (48.5) 95 (42.4) 0.85 (0.60-1.22) 0.376 84 (42.6) 0.84 (0.58-1.22) 0.361 11 (40.7) 0.93 (0.39-2.22) 0.873 36 (36.1) 0.64 (0.36-1.15) 0.137
GG 21 (6.3) 25 (11.2) 1.73 (0.92-3.26) 0.090 20 (10.2) 1.54 (0.79-3.01) 0.199 5 (18.6) 3.27 (1.03-10.42) 0.044 7 (11.5) 1.57 (0.61-4.03) 0.342
AG + GG 183 (54.8) 120 (53.6) 0.95 (0.68-1.34) 0.776 104 (52.8) 0.92 (0.65-1.32) 0.656 16 (49.3) 1.20 (0.54-2.67) 0.653 43 (47.6) 0.75 (0.43-1.29) 0.296
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hancers (unfavorable genotypes). After stepwise regression
analyses, two (p.Arg72Pro in TP53 and p.Arg952Lys in
ATP7B gene) and three (p.Ile1145 = in ABCB1, p.
Asp1853Asn in ATM and p.Ser406Ala in ATP7B gene)
polymorphisms remained in the respective models for
each group. The results of analyzing favorable geno-
types showed strong significant reduction of ovarian
cancer risk in the presence of both variants (OR 0.50;
95% CI 0.30-0.83; p = 0.008). In the analysis of cumulative
unfavorable effects we found that ovarian cancer risk pro-
gresses in the presence of chosen SNPs, resulting in the
highest risk for carriers of all three polymorphisms (OR
7.47; 95% CI 2.08-26.85; p = 0.002) (Table 3).
Survival analysis of SNPs related to cancer risk
The top SNPs related to cancer risk were subjected to
survival analysis for the group of ovarian cancer patients
treated with paclitaxel and cisplatin. In the univariate
analysis two polymorphisms tended to influence overall
survival. Heterozygotes for p.Arg72Pro in the TP53 gene
appeared to have better survival and lower risk of death,
when compared to major homozygotes (Figure 1A). An
opposite effect was noted for PGR p.Val660Leu variant,
for which minor homozygotes appeared to cause shorter
overall survival and higher risk of death (Figure 1B).
However, none of these polymorphisms was a significant
prognostic factor after adjustment to FIGO and tumor
histotype. As for the progression-free survival, multivari-
ate model adjusted to FIGO and ovarian cancer histo-
type, we identified two variants as independent factors.
Higher risk of disease progression was associated with
presence of genotypes lacking a major p.Ser893Ala/Trp
polymorphism (HR 2.14; 95% CI 1.07-4.28; p = 0.031) in
the G allele of ABCB1 and with the presence of major
homozygote GG of p.Asp1853Asn in the ATM gene (HR
2.32; 95% CI 1.06-5.10; p = 0.036) (Table 4). For these
high-risk genotypes we performed the analysis of cumu-
lative progression risk in order to calculate the gene dos-
age effect. The results had shown significant shortening
of PFS (Figure 1C) for the carriers of one and both men-
tioned variants; also, the accumulation of both riskTable 3 Cumulative effect of favorable and unfavorable geno
Analysis Polymorphisms Number of variants
Favorable effect p.Arg952Lys ATP7B 0
p.Arg72Pro TP53 1
2




Statistically significant analyses are in bold.factors was responsible for higher risk of ovarian cancer
progression in comparison with persons who did not
carry any of the unfavorable genotypes (HR 3.81; 95% CI
1.38-10.51; p = 0.010).
Discussion
The influence of low-penetrance common genetic vari-
ants selected for this study on ovarian cancer risk and
survival was not extensively studied yet. Here, in a case–
control study we analyzed 12 polymorphic variants and
two deletions in nine genes. The case group reflected
consecutive cancer cases which included patients with
germline mutation in BRCA genes and persons who also
developed breast cancer. Both groups under study
belonged to Slavic ethnic group with specific founder
mutations in BRCA1/2 genes [18,19]. Multicenter ana-
lyses [20-22] including our own results are done on
much larger groups but they often show inconsistent re-
sults for the different populations included in the study
and in our analysis we wanted to avoid this problem
even though the population under study was smaller.
The protein product of progesterone receptor gene
(PGR) participates in the regulation of epithelial cell pro-
liferation and thus plays an important role in ovarian
carcinogenesis. Its expression levels vary several fold in
different histological types of ovarian cancer. We wanted
to find out whether polymorphic variants of this gene
could modulate the risk of ovarian cancer. Previous
studies had shown that polymorphic variants of PGR
were connected with significant increase of ovarian can-
cer risk (overall [23,24], or limited only to the endome-
trioid histotype [20]). We chose 2 SNPs (p.Val660Leu
and rs474320) from PROGINS allele and one in the pro-
moter region of this gene (rs10895068). In our analysis
none of them significantly altered the ovarian cancer risk
in the groups under study, except for the BRCA1+ group
where, for heterozygotes for p.Val660Leu polymorphism,
a significant increase of cancer risk was found. This re-
sult indicates that p.Val660Leu effect is specific only for
carriers of germline mutations in BRCA genes, and this
finds support in the actual differences between ER and
PGR gene expression in sporadic and hereditary breasttypes on ovarian cancer risk
Controls n (%) Cases n (%) OR (±95%CI) P
52 (15.7) 46 (23.78) 1 (ref)
162 (48.8) 96 (49.5) 0.67 (0.42-1.07) 0.095
118 (35.5) 52 (26.8) 0.50 (0.30-0.83) 0.008
27 (8.1) 3 (1.06) 1 (ref)
95 (28.6) 42 (22.3) 3.98 (1.13-13.97) 0.030
163 (49.1) 104 (55.3) 5.74 (1.69-19.50) 0.005
47 (14.2) 39 (20.8) 7.47 (2.08-26.85) 0.002
Figure 1 Survival analysis of ovarian cancer-related SNPs. A. overall survival and risk of death for TP53 p.Arg72Pro; B. overall survival and risk
of death for PGR p.Val660Leu; C. progression-free survival and cumulative risk of progression for unfavorable PFS factors (ATM p.Asp1853Asn GG
genotype and ABCB1 p.Ser893Ala/Trp TT + TA genotypes group).
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Ovarian cancer is also a hormone-dependent malig-
nancy, so the role of PGR gene in BRCA1+ and BRCA1-
ovarian cancers can be different as well. There is also
the possibility that the PROGINS variant is co-inherited




FIGO 1 + 2
3 + 4
ABCB1 p.Ser893Ala p.Ser893Thr rs2032582 Common allele carriers (GG
Rare genotypes (AT + TT)
ATM p.Asp1853Asn rs1801516 Rare allele carriers (GA + AA
Common homozygote (GG
Statistically significant analyses are in bold.were also obtained for the rare heterozygotes TA of p.
Ser893Ala/Trp polymorphism in ABCB1 gene. They had
a 5-fold higher risk of developing ovarian cancer when
compared to the reference homozygotes. ABCB1 gene
product transports a wide range of substrates and it confers
resistance to a vast array of clinically and toxicologicallyCases n (%) HR (±95% CI) P
57 (44.2) 1 (ref)
72 (55.8) 5.04 (2.05-12.37) 0.0004
58 (46.0) 1 (ref)
68 (54.0) 2.19 (1.03-4.64) 0.041
+ GT + GA) 101 (80.2) 1 (ref)
25 (19.8) 2.14 (1.07-4.28) 0.031
) 87 (61.0) 1 (ref)
) 39 (39.0) 2.32 (1.06-5.10) 0.036
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product among carriers of rare allele seems to alter the ef-
flux of potentially cancerogenic xenobiotics. Such modifi-
cation could increase the risk of developing cancer,
especially in the group of persons affected by germline
mutation in BRCA1 gene, which affects the DNA repair.
Similar associations between the common genetic variants
(SNPs) and high-penetrance germline mutations, which
additionally modify the risk of developing ovarian cancer,
were also found in genome-wide association studies car-
ried out on large cohorts [26]. The authors did not
exclude the existence of other modifying risk variants of
other genes. Earlier, similar associations with other genes
were also found in breast cancer patients also carrying
germline mutations in BRCA1/2 genes [27]. However,
analyses done on small groups brought conflicting results.
Jakubowska et al. found no significant association between
the PGR gene polymorphisms and the ovarian cancer risk
in the group of 146 ovarian cancer patients carrying germ-
line mutation in BRCA1 gene [28]. Also, in heterozygotes
for ABCG2 polymorphism p.Gln141Lys we found a trend
towards decreased risk of ovarian cancer. Similar effects,
or no effects at all, were found in other analyses per-
formed for different types of cancer [29,30].
In our analysis a significant increase of cancer risk was
observed for ATM p.Asp1853Asn heterozygotes which
corroborates the finding that missense polypeptides will
compete with normal ATM polypeptides in complex for-
mation, and that the functionally abnormal missense poly-
peptide will sequester key regulators or substrates into
nonfunctional complexes, resulting in dominant negative
cellular phenotype [31]. Opposite results were found for
TP53 p.Arg72Pro variant. In heterozygotes, we observed a
protective effect against tumorigenesis. This means that a
lesser number of heterozygotes developed ovarian cancer;
moreover, if they were diagnosed with malignancy, their
overall survival was better than that of homozygotes. Both
effects in ATM and TP53 genes were found only in the
total group of patients and the patients without germline
mutation in BRCA1 gene, but not in the BRCA1+ group.
Similar results were also observed by others for breast
cancer patients carrying germline mutation in BRCA1
[32]. It can be concluded that variants under study modify
sporadic cancer risk and have no effect on familial ovarian
cancer [25,33]. The Arg72 variant exists only in humans
and is more efficient in inducing apoptosis and suppressing
transformation than the Pro72 allele, which can explain the
protective effect found in our analysis [34].
The protective effect of the haplotype GSTT1wt/
GSTM1null was observed for all patients and for the
sporadic ovarian carcinoma group. The significant ef-
fect for the third glutathione transferase under study,
GSTP1, was noted only in the familial ovarian cancer
group where the carriers of minor GG homozygotewere at higher risk of developing cancer. Other researchers
did not find any correlations between GSTT1, GSTM1
alone or haplotypes and ovarian cancer risk [35-38]. We
observed also the deviation from HWE equilibrium in the
control group for the GSTP1 gene. This effect was ob-
served in this analysis only, so we hypothesize that it is
not connected with genotyping errors, population stratifi-
cation or some other artifacts but rather with the particu-
lar gene under study. HWE deviations could arise through
important biological mechanisms. In particular, genetic
variants having a recessive effect on the successful
fertilization and/or development of an embryo might be
manifested through such deviations in an unselected sam-
ple of “control” subjects [39]. Similar deviation from HWE
for GSTP1 was also noted by others [40].]. Glutathione
and its transpherases may regulate the ability of each indi-
vidual to metabolize environmental carcinogens, which is
noticed especially well in smoking-related tumors [41].
Our results show that the genetic variants in glutathione
transpherases genes are also able to modify the risk of
other cancers which are indirectly related to tobacco use.
Breast and ovarian cancer group shows different be-
havior from the two groups described earlier. The pres-
ence of multiple tumors in one patient is associated with
a higher likelihood of genetic susceptibility [42]. In our
study, the only significant associations with ATM p.
Asp1853Asn and ATP7B p.Arg952Lys variants indicated
the importance of cell cycle and cellular copper metabol-
ism control systems in the cancer-prone phenotype.
However, more than one primary malignancy occurs
rarely, so our group under study was small and the re-
sults of statistical analyses should be taken with caution.
In this study we observed several strong gene-dosage
effects. The combined impact of the studied SNPs on
ovarian cancer risk shows that ovarian carcinoma can be
treated as a polygenic disease partially dependent on the
accumulation of unfavorable genetic factors. In our ana-
lysis, the unfavorable factors which increased ovarian
cancer risk over seven times, prevailed over favorable
factors which cut the ovarian cancer risk by half. We
can conclude, that carrying unfavorable variants of low-
penetrance polymorphisms can increase (OR 7.47 in our
study) the ovarian cancer risk to the level similar to the ef-
fect of carrying germline mutation in a high-penetrance
gene (OR 8.6 calculated for Canadian population [43]). As
for the survival analyses, it was evident that accumulation
of relatively weak genetic variants (ABCB1 p.Ser893Ala/
Trp and ATM p.Asp1853Asn) may significantly enhance
the risk of progression after paclitaksel/cisplatin treat-
ment. The trinucleotide polymorphism in the ABCB1
gene is a widely studied variant linked to altered trans-
porter activity, although the results reported by different
authors are inconsistent. It should be noted that in recent
large study performed on over four thousand invasive
Tecza et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:2 Page 10 of 11ovarian cancer patients the p.Ser893Ala/Trp polymorph-
ism had no impact on patients’ survival [21]. The ATM
variant is believed to be responsible for reduced ATM
kinase activity and could be the reason for more efficient
cisplatin-related apoptosis [31,44]. It could be also the
reason why in our analyses the common homozygote of
p.Asp1853Asn variant was connected with higher risk of
disease progression in the multivariate model.
Conclusions
Significant associations have been found between the
variants of genes involved in: cell cycle regulation, DNA
repair, active transport of chemical compounds, detoxi-
fication, hormonal regulation of progesterone and the
risk of ovarian cancer together with a strong gene-dosage
effect. This finding enables to work out the polygenic gen-
etic tests for the non carriers of BRCA1/2 mutation who
could have similar risk of developing ovarian cancer as the
carriers of germline mutations in BRCA genes if they
inherited unfavorable variants.
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